Regulus Therapeutics is a San Diego-based biopharmaceutical company focused on developing microRNA-targeted drugs for orphan kidney diseases, including its candidate RGLS8429 for autosomal dominant polycystic kidney disease. The company went public on October 4, 2012, and has 28 employees.
Preston Klassen sold 31,445 shares of RGLS on 13 January at $1.26 per share, worth a total of $40K. They now own 36,055 RGLS shares, or a 47% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
